CANCER IS DETECTED TOO LATE
Exact Sciences is changing the way we think about detecting and treating cancer. As a leader in cancer testing, we are committed to providing earlier answers and life-changing treatment guidance.
Effective August 2, 2022, mdxhealth has acquired the Oncotype DX GPS (Genomic Prostate Score) test from Exact Sciences. To help ensure a smooth transition for patients, continue to place orders for this test through the existing Exact Sciences portal until further notice. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the Oncotype DX GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the following press release. Questions? Email: gps@mdxhealth.com
SUPPORTING PATIENTS
AT EVERY STEP
Exact Sciences’ current portfolio of products primarily focuses on colorectal, breast and prostate cancers, with research and development looking at the top 15 deadliest cancers, including multi-cancer testing.
Our vision is to eradicate cancer and the suffering it causes through tests that detect it earlier and provide guidance for successful treatment.
Screening
Prognosis/ Therapy Selection
Minimal Residual Disease
Recurrence Monitoring
Therapy Selection
EARLIER CANCER DETECTION STARTS HERE
At Exact Sciences, we are cancer fighters. We are united by our mission to change lives by providing earlier, smarter answers. Through advances in cancer detection and treatment guidance, we will help eradicate the disease and the suffering it causes.
RIGOROUS SCIENCE.
REVOLUTIONARY SOLUTIONS.
Our teams use their scientific expertise to continuously innovate.
WORLD-CLASS SERVICE FOR
PHYSICIANS AND PATIENTS
Exact Sciences Laboratories are dedicated to delivering the most accurate test results to support informed decision making.